Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Olesia Kellezi"'
Publikováno v:
Cancer Treatment and Research Communications, Vol 25, Iss , Pp 100251- (2020)
Introduction: Immune checkpoint inhibitors (CPIs) were recently approved in advanced clear cell renal cell carcinoma (RCC) and could be a promising option for metastatic RCC with sarcomatoid differentiation (sRCC) which otherwise carry a poor prognos
Externí odkaz:
https://doaj.org/article/9762f402e20a46e09a12e8c70dd1c421
Autor:
Alicia Ali, Scott T. Tagawa, Frank C. Cackowski, Vaibhav G. Patel, Divya Natesan, Clara Hwang, Michael Pierro, Ajjai Alva, Joseph J. Park, Tanya B. Dorff, Bicky Thapa, Susan Halabi, Colin Pritchard, Michael T. Schweizer, Rohan Garje, Abhishek Tripathi, Rana R. McKay, Albert Jang, Marcin Cieslik, Catherine Handy Marshall, Laura S Graham, Justin Shaya, Tomi Jun, Landon Carter Brown, Alleda Mack, Elisabeth I. Heath, Vadim S. Koshkin, Christopher Nguyen, Pedro C. Barata, Olesia Kellezi, Deepak Kilari, Mehmet Asim Bilen, Sanober Nusrat, Luna Acharya, Deepak Ravindranathan, Matthew Labriola, Andrew J. Armstrong, William Oh, Shuang R. Chen, Angelo Cabal, Amanda Pilling
Publikováno v:
Prostate cancer and prostatic diseases. 25(3)
Purpose Prostate cancer is a heterogeneous disease with variable clinical outcomes. Despite numerous recent approvals of novel therapies, castration-resistant prostate cancer remains lethal. A “real-world” clinical-genomic database is urgently ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bb5e8ff5d28a119c1d3110b7b16a48d
https://pubmed.ncbi.nlm.nih.gov/34363009
https://pubmed.ncbi.nlm.nih.gov/34363009
Publikováno v:
Cancer Treatment and Research Communications, Vol 25, Iss, Pp 100251-(2020)
Introduction Immune checkpoint inhibitors (CPIs) were recently approved in advanced clear cell renal cell carcinoma (RCC) and could be a promising option for metastatic RCC with sarcomatoid differentiation (sRCC) which otherwise carry a poor prognosi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed8f85fc3c94395541250a2ad492b0fe
https://pubmed.ncbi.nlm.nih.gov/33310369
https://pubmed.ncbi.nlm.nih.gov/33310369
Autor:
Laura Graham, Edward Green, Joseph J. Park, Olesia Kellezi, Clara Hwang, Pedro C. Barata, Mehmet Asim Bilen, Deepak Kilari, Melissa Clingerman, Abhishek Tripathi, Matthew Labriola, Shoshana Rothstein, Rohan Garje, Vadim S Koshkin, Vaibhav G. Patel, Tanya B. Dorff, Andrew J. Armstrong, Rana R. McKay, Ajjai Shivaram Alva, Michael Thomas Schweizer
Publikováno v:
Journal of Clinical Oncology. 40:129-129
129 Background: Pathogenic HRR gene mutations may confer sensitivity to PARP inhibitors (PARPi) and/or platinum chemotherapy (chemo). While pts harboring mutations in BRCA1/2 appear to benefit from these DNA damaging therapeutics, outcomes data for t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::777de6f4ad51a4a484660ed3fe4a7d45
https://doi.org/10.1200/jco.2022.40.6_suppl.129
https://doi.org/10.1200/jco.2022.40.6_suppl.129
Autor:
Megan N. Dahl, Christopher Su, Daniel C. Winfield, Reema Hamasha, Vincent T. Ma, Stephanie Erickson, Sabrina Yancey, Jessica Lora, Jeremy M. G. Taylor, Alicia Ali, Miloni A. Shah, Miriam Hu, Stephanie Daignault-Newton, Ajjai Alva, Olesia Kellezi, Michael D. Green, Leah Kiros, Hannah M. Balicki
Publikováno v:
Urol Oncol
Several immune checkpoint inhibitors (ICIs) are FDA approved for treatment of genitourinary (GU) malignancies. We aim to determine demographic and clinicopathologic characteristics that significantly affect clinical outcomes in patients with advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3febb890e0d161c8df3e259292152f14
https://doi.org/10.1016/j.urolonc.2021.01.006
https://doi.org/10.1016/j.urolonc.2021.01.006